Cell therapy

Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and potentially multiple scientists, how can […]

Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and potentially multiple scientists, how can […]

Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and potentially multiple scientists, how can […]

Chimeric Antigen Receptor or CAR-T cells, a new form of immunotherapy with genetically engineered immune system cells, has been approved for the treatment of multiple myeloma, a type of blood cancer.  Context  In a case study published in Nature Medicine, Sinai scientists reported a previously unknown neurological side effect resembling symptoms Parkinson’s Disease in a patient […]

Over the last decade, groundbreaking chimeric antigen receptor (CAR) T-cell immunotherapies have become a well-established cancer treatment modality. Clinical research continues to demonstrate the encouraging potential this approach holds for treating a wide array of conditions while increasing safety, tolerability, and efficiency in manufacturing. Atara Biotherapeutics, a California-based biotechnology company, seeks to harness the immune […]

CAR T cell technology provides the foundation for established immunotherapies against certain types of blood cancer and holds great promise for the fight against many solid tumours too. One major drawback of conventional CAR T cell technology, which relies on a single target antigen, is the lack of tumour-associated antigens (TAAs) that are truly specific for cancer cells. […]

Listen to this article on the DDW Podcast: Marjie Hadad talks to cell therapy expert and Kadimastem CEO Asaf Shiloni about the potential of cell therapy.  “I am attracted to cell therapy because traditional medicine has reached its limitation in treating the ailments of the 21st century,” says Asaf Shiloni, 20-year biotechnology executive, cell therapy expert and CEO of Kadimastem.  He continues: “It’s known […]

Ncardia, developer of stem cell-based solutions for drug discovery and cell therapy, has secured more than $60 million in capital through a strategic partnership with Kiniciti, a US-based investment platform.  Ncardia’s capabilities include bio-reactor-based scalable manufacturing of iPSC derived cells, assay development, disease modeling, and cell-based screening.  Alain Parthoens, Ncardia’s Chairman, said: “Kiniciti is uniquely suited to help Ncardia expand globally and to […]

Scientists at the Francis Crick Institute have found how the immune system triggers an ‘emergency’ dendritic cell response during infection, with dendritic cells at the site of infection being reinforced by new cells which travel from the bone marrow.   Dendritic cells have an important role in the immune system, detecting infectious bacteria, fungi or viruses […]

Human cell coding company bit.bio has closed a Series B financing of $103 million to accelerate the clinical development of the company’s cell coding technology opti-oxTM, a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells.  The funding will also support the continued […]

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of adoptive cell transfer therapies, such as […]

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of adoptive cell transfer therapies, such as […]

GammaDelta Therapeutics has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML). GDX012 is an allogeneic, non-engineered, variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy manufactured from healthy donor blood.  AML is the most common form of acute leukaemia in adults with an estimated 20,000 new cases per year in the […]

Anti-androgen therapy is commonly used to treat patients with advanced prostate cancer which has spread to the bones, however, the treatment may be fuelling bone cancer spread.  Dr Nathalie Bock from QUT Centre for Biomedical Technologies focused her research on bone metastases from breast and prostate cancers. The research team investigated its hypothesis that traditional anti-androgen therapy […]

Professor of Cellular Immunology at the University of Dundee’s School of Life Sciences, Doreen Cantrell, has been selected to join GSK’s Immunology Network, a programme designed to embed academic scientists in GSK laboratories with the goal to broaden scientific insight and drive major breakthroughs in applied immunology.  Professor Cantrell is an immunologist and an authority […]

Natural killer (NK) cell therapies have the potential to be an effective, off-the-shelf treatment for a range of cancers. Analysis of NK cell therapies, currently in development, reveals that 57% of these are allogeneic therapies, and although development in haematological indications is more advanced, there are a high number of therapies being investigated in solid tumours, says GlobalData, data […]